Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To investigate the safety and efficacy of a fixed dose of intravenous BAY 58-2667 (50 μg/h, 100 μg/h, or 150 μg/h) over at least 24 hours and up to 48 hours in subjects with ADHF needing parenteral pharmacotherapy. The focus of the study will be to evaluate the subjects well-being based on the subjects symptoms and reported outcomes ie, Dyspnea VAS, Likert score, and EQ-5D at baseline, 8 hours, 24 hours, 48 hours, at discharge (or at Day 7), and at the follow-up visit, and the global clinical assessment by the physician at 8 hours, 24 hours and 48 hours. The primary efficacy endpoint will be the change from baseline to 8 hours (or Last Observation Carried Forward [LOCF]) on the Dyspnea VAS
Critère d'inclusion
- Acute Decompensated Chronic Congestive Heart Failure (ADHF)